Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Appili Therapeutics Inc
T.APLI
Alternate Symbol(s):
APLIF
Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti...
-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:APLI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
Next
(1912)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Apr 02, 2024 10:08am
Appili Therapeutics Sign Definitive Agreement to be Acquired
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR
...more
(9)
•••
BradlTheGerman
X
View Profile
View Bullboard History
Post by
BradlTheGerman
on Dec 17, 2023 2:29am
ATI -1701
Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024. The goal of the ATI-1701
...more
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 23, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(9)
•••
BradlTheGerman
X
View Profile
View Bullboard History
Post by
BradlTheGerman
on Dec 16, 2023 3:45pm
New shareholder.
I have bought my first 75.000 shares over the last two weeks. I am going to double or triple my position over the next year. I will hold my shares until 2028. I am sure for 150 percent that I
...more
(10)
•••
mba123ccu
X
View Profile
View Bullboard History
Post by
mba123ccu
on Sep 25, 2023 8:57am
FDA approval for ATI-1501
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension Very important milestone achieved......looking forward to more of this positive news in the near
...more
(8)
•••
RJSullivan
X
View Profile
View Bullboard History
Post by
RJSullivan
on Jul 17, 2023 3:01pm
Seems severely under-valued. Big potential
This stock looks to have been severely punished in the past and perhaps folks are starting to look at their pipeline and realize that it's severely undervalued. Being able to combat anaerobic
...more
(15)
•••
opsd1
X
View Profile
View Bullboard History
Post by
opsd1
on Nov 21, 2022 1:20pm
Big bids coming in now.
What's up?
(15)
•••
opsd1
X
View Profile
View Bullboard History
Post by
opsd1
on Nov 15, 2022 10:14am
APLI Secures US$14 million from US DoD for Biodefense
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy https://stockhouse.com/news/press
...more
(49)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 14, 2022 3:47pm
News Update w Radius Research and $APLI CEO Armand Balboni
News Update: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni - Develop Leishmaniasis Treatment ATI-1801 - https://www.youtube.com/watch?v=YyE8zLvWApM {^youtubevideo|(width)425
...more
(10)
•••
ecanadian2
X
View Profile
View Bullboard History
Post by
ecanadian2
on Apr 12, 2022 8:25pm
yes, lots of potential and appears to be a well run
company but: * $3.6M they raised will be used almost in full to pay off the previous loan * the interest on the new loan will be at least $1/4 million a year ... and APLI has precious little money on
...more
(49)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 11, 2022 10:32am
Webinar Recap w Radius Research & $APLI CEO Armand Balboni
Webinar Recap: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni - Drug Development Focused on Infectious Diseases - Pitch, Deep Dive, and Q&A - https://www.youtube.com/watch?v=xGrmHACzU7c
...more
(49)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 04, 2022 10:25am
Webinar w $APLI CEO Armand Balboni Fri Apr 8 @ 12:30PM ET
Webinar - Appili Therapeutics (APLI) w/ CEO Dr. Armand Balboni Fri, Apr 8 at 12:30pm ET / 9:30am PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar
...more
(1912)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Mar 29, 2022 2:23pm
Appili Therapeutics Announces Non-Convertible Secured Loan
March 29, 2022 07:36 AM Eastern Daylight Time HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company
...more
(10)
•••
ecanadian2
X
View Profile
View Bullboard History
Post by
ecanadian2
on Mar 16, 2022 12:37am
Will Lind be converting $3 mil into shares after Mar 18?!!
Will Lind be converting $3 million into shares after Friday March 18?! That would be 10s of millions of shares unloaded on the illiquid APLI market. Scary ... still no update from APLI on this. "
...more
(1912)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Feb 28, 2022 7:58am
Over US$10 M in New Funding from US Department of Defense
February 28, 2022 07:40 AM Eastern Standard Time HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical
...more
(1912)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Feb 08, 2022 7:27am
Appili Therapeutics Expands ATI-1501 Commercial Agreement
February 08, 2022 07:17 AM Eastern Standard Time HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical
...more
Prev
1
2
3
4
5
6
7
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth